Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder
NCT04982796Phase 2Active, not recruiting
- Sponsor
- Portland VA Research Foundation
- Start
- Jul 2022
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised trial of psilocybin in methamphetamine use disorder (MUD) (2 arms), sponsored by Portland VA Research Foundation. Primary endpoints: Acceptability at 42 days and Proportion of patients who complete the intervention and follow-up at 180 days. Started Jul 2022; status: active, not recruiting.
02
Drugs
psilocybin
03
Conditions
methamphetamine use disorder (MUD)
Beyond the preview
Go deeper on NCT04982796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04982796.